The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer.
A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.
Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.
Zev A. Wainberg, MD, discusses the evaluation of liposomal irinotecan plus 5-fluorouracil leucovorin, and oxaliplatin vs nab-paclitaxel plus gemcitabine in the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.
Both veliparib plus total neoadjuvant therapy and pembrolizumab plus total neoadjuvant therapy failed to improve short-term outcomes in unselected patients with locally advanced rectal cancer.
Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.
Josep Tabernero, MD, PhD, discusses findings from the phase 3 SUNLIGHT trial investigating the combination of bevacizumab plus trifluridine/tipiracil vs TAS-102 alone in patients with refractory metastatic colorectal cancer.
Laura Dawson, MD, FRCPC, discusses results from the phase 3 NRG/RTOG 1112 trial of stereotactic body radiation therapy plus sorafenib compared with sorafenib alone in patients with locally advanced hepatocellular carcinoma.
The combination of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab demonstrated early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma, according to updated results from the phase 1 SGNS40-001 study.
Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.
The addition of stereotactic body radiation therapy to sorafenib led to an improvement in overall survival, progression-free survival, and time to disease progression compared with sorafenib alone in patients with locally advanced, hepatocellular carcinoma.
The addition of nab-paclitaxel to gemcitabine and cisplatin did not result in a statistically significant improvement in overall survival over gemcitabine/cisplatin alone in patients with newly diagnosed, advanced biliary tract cancers.
First-line treatment with the combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin produced a clinically meaningful and statistically significant improvement in overall survival and progression-free survival vs nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma, according to results from the phase 3 NAPOLI 3 trial.
Kohei Shitara, MD, discusses the evaluation of the combination of zolbetuximab plus mFOLFOX6 in patients with CLDN18.2–positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.
Findings from the phase 2 CISLC-12 study show favorable safety and efficacy signals for patients with unresectable hepatocellular carcinoma treated with the combination of envafolimab, lenvatinib, and transarterial chemoembolization.
The presence of anti-drug antibodies appeared to have no effect on efficacy or safety of durvalumab monotherapy or the STRIDE combination of durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma.
In the first-line treatment of patients with advanced hepatocellular carcinoma, a combination of pembrolizumab plus lenvatinib yielded similar health-related quality of life scores as lenvatinib plus placebo, according to a HRQOL analysis of the phase 3 LEAP-002 study.
Patients with HER2-overexpressing metastatic or advanced gastric/gastroesophageal junction adenocarcinoma treated with HER-Vaxx plus standard-of-care chemotherapy had a statistically significant survival benefit compared with those who received chemotherapy alone.
Frontline zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival vs placebo/mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma, according to primary phase 3 data from the SPOTLIGHT trial.
Nivolumab in combination with chemotherapy or ipilimumab maintained a clinically meaningful overall survival benefit vs chemotherapy alone in patients with treatment-naïve advanced esophageal squamous cell carcinoma.
The combination of nivolumab (Opdivo) and chemotherapy continued to provide a clinically meaningful long-term survival benefit and deeper responses than chemotherapy alone in previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, according to 3-year follow-up data from the phase 3 CheckMate-649 trial.
Neoadjuvant treatment with the combination of tremelimumab and durvalumab produced responses and was well tolerated in patients with mismatch repair–deficient and microsatellite instability–high, Epstein-Barr virus–negative gastric or gastroesophageal junction adenocarcinoma.
Clinicopathological features of HER2-low advanced gastric cancer were distinct and distinguishable from those of HER2-positive or -negative disease, according to retrospective findings from a single-institution study that were presented at the 2022 Gastrointestinal Cancers Symposium.